The Biotech Trader Handbook: A Fast, Simplified & Efficient Guide to Potentially Generate Outsized Returns in Biotech Using Options

by T. Ayers Pelz

Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price.This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities.In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient approach to identify, analyze & execute trading strategies using options.The following topics, amongst others, are covered in this Description of the FDA drug trial process, from pre-clinical to Phase III & beyond* Identification, categorization & organization of small cap biotech companies* Structured & streamlined approach to assess small cap biotech companies* Notes on trading strategy & tactics* Detailed description of option trading structures best suited for small cap biotechThis book is an absolute "must have" for individuals thinking about trading in the fast paced and often confusing world of small cap biotech.

116 pages, Paperback

First published February 9, 2010

Reviews

[Philski · Rating 5 out of 5]

Excellent book on biotech trading, worth every penny of the $20 or so it goes for on Amazon. The first chapter covers the major events that go into drug approval (the catalysts) with suggestions on which make the biggest impact. The rest of the book covers how to do basic research, set up trades and best set up to profit from binary events, much of which can apply to other binary events (like patent infringement lawsuits).

[James · Rating 5 out of 5]

if you trade biotech then you should read this. otherwise have fun staying poor

[Kai · Rating 3 out of 5]

Legitimately didn't understand anything in 2020, now its the reality for my reptilian brain that loves where biotech meets markets